Wall Street Journal Op-Ed on Bioidentical Hormones

Last month, the Wall Street Journal ran an Op-Ed response to its article on bioidentical hormones. In it, many of the misconceptions regarding these treatments were addressed by members of the Bioidentical Hormone Initiative, a non-profit group of physicians dedicated to patient/physician education. These days, women are empowered to make informed decisions about any health treatment, and this article calls for more clarity to end the confusion about hormone treatment. Really, it all comes down to choice - and women deserve more choices. Read more here.

Perhaps equally as interesting as the content of the piece is that major financial media outlets like the WSJ are paying attention to menopause. Yes, there is money to be made here, yes women are worthy of investing in, yes women deserve - and will spend money on - quality treatments. Financiers, take note. Menopause is a worthy investment.